Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus

JAMA Internal Medicine

Volumn 174, Issue 8, 2014, Pages 1227-1234

  Vijan, Sandeep ^a,b   Sussman, Jeremy B ^a,b   Yudkin, John S ^c   Hayward, Rodney A ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

AGED; BLOOD; COST OF ILLNESS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HUMAN; METABOLISM; MIDDLE AGED; PATIENT PREFERENCE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; COST OF ILLNESS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MARKOV CHAINS; MIDDLE AGED; MODELS, STATISTICAL; PATIENT PREFERENCE; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84903636684     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.2894     Document Type: Article

References (72)

1. National Committee for Quality Assurance. HEDIS 2013. 2013. http://www.ncqa.org/HEDISQualityMeasurement/HEDISMeasures/HEDIS2013.aspx. Accessed October 15, 2013.
2. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care. 2013;36(suppl 1): S11-S66.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131): 837-853.
4. ACCORD Study Group; ACCORD Eye Study Group; Chew EY, AmbrosiusWT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010; 363(3): 233-244.
5. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359 (15): 1577-1589.
6. Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control inmicrovascular complications in type 2 diabetes. Ann Intern Med. 1997;127(9): 788-795.
7. Ray KK, Seshasai SR,Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: ameta-analysis of randomised controlled trials. Lancet. 2009;373(9677): 1765-1772.
8. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343: d4169.
9. Yudkin JS, Richter B, Gale EA. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia. 2010;53(10): 2079-2085.
10. Control Group; Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes [published correction appears in Diabetologia. 2009;52(1): 2470].
11. Diabetologia. 2009;52(11): 2288-2298.
12. Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011;343: d6898.
13. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6): 421-431.
14. Vijan S, Hayward RA, Ronis DL, Hofer TP. Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens. J Gen Intern Med. 2005;20(5): 479-482.
15. Huang ES, Shook M, Jin L, Chin MH, Meltzer DO. The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. Diabetes Care. 2006;29(2): 259-264.
16. Timbie JW,Hayward RA,Vijan S. Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. Arch Intern Med. 2010;170(12): 1037-1044.
17. American Geriatrics Society. Choosing wisely: five things physicians and patients should question. 2013. http://americangeriatrics.org/health-care- professionals/clinical-practice/clinical-guidelines-recommendations/ choosingwisely. Accessed November 7, 2013.
18. Brown AF, Mangione CM, Saliba D, Sarkisian CA; California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for EldersWith Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J AmGeriatr Soc. 2003;51(5)(suppl guidelines): S265-S280.
19. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, MillerME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24): 2545-2559.
20. Nissen SE,Wolski K. Effect of rosiglitazone on the risk ofmyocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24): 2457-2471.
21. Nissen SE,Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk formyocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170(14): 1191-1201.
22. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352(9131): 854-865.
23. Boye KS, Matza LS,Walter KN, Van Brunt K, Palsgrove AC, Tynan A. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ. 2011;12(3): 219-230.
24. Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res. 2007;16(7): 1251-1265.
25. Huang ES, Brown SE, Ewigman BG, Foley EC, Meltzer DO. Patient perceptions of quality of life with diabetes-related complications and treatments. Diabetes Care. 2007;30(10): 2478-2483.
26. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011;154(8): 554-559.
27. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA. 2000;283(7): 889-896.
28. Schmittdiel J, Vijan S, Fireman B, Lafata JE, Oestreicher N, Selby JV. Predicted quality-adjusted life years as a composite measure of the clinical value of diabetes risk factor control. Med Care. 2007;45(4): 315-321.
29. Rosen AB, Hamel MB,Weinstein MC, Cutler DM, Fendrick AM, Vijan S. Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med. 2005;143(2): 89-99.
30. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321 (7258): 405-412.
31. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. I. model construction and assumptions. Diabetes Care. 1997; 20(5): 725-734.
32. Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial [published correction appears in JAMA. 1997;278(1): 25].
33. JAMA. 1996;276(17): 1409-1415.
34. Brown GC, Brown MM, Sharma S, Brown H, Gozum M, Denton P. Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications. 2000;14(1): 18-24.
35. Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors ofmyocardial infarction. Med Decis Making. 1993;13: 161-165.
36. Mathias SD, Bates MM, Pasta DJ, Cisternas MG, Feeny D, Patrick DL. Use of the Health Utilities Index with stroke patients and their caregivers. Stroke. 1997;28(10): 1888-1894.
37. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA. 1988;260(19): 2864-2871.
38. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8): 968-983.
39. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology. 1991;98(5)(suppl): 766-785.
40. Ferris FL III. How effective are treatments for diabetic retinopathy? JAMA. 1993;269(10): 1290-1291.
41. Lewis EJ, Hunsicker LG, ClarkeWR, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12): 851-860.
42. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12): 861-869.
43. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12): 870-878.
44. Ballard DJ, Humphrey LL, Melton LJ III, et al. Epidemiology of persistent proteinuria in type II diabetes mellitus: population-based study in Rochester,Minnesota. Diabetes. 1988;37(4): 405-412.
45. Humphrey LL, Ballard DJ, Frohnert PP, Chu CP, O'Fallon WM, Palumbo PJ. Chronic renal failure in non-insulin-dependent diabetes mellitus: a population-based study in Rochester,Minnesota. Ann Intern Med. 1989;111(10): 788-796.
46. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287(19): 2542-2551.
47. Eastman, RC. Neuropathy in diabetes. In: National Diabetes Data Group, eds. Diabetes in America. 2nd ed. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995: 339-348.
48. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121(1, pt 2): 293-298.
49. Centers for Disease Control and Prevention (CDC). National Health and Nutrition Examination Survey: NHANES 2009-2010. 2013. http://wwwn.cdc.gov/nchs/ nhanes/search/nhanes09-10.aspx. Accessed October 24, 2013.
50. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care. 1997;20(5): 735-744.
51. Augustovski FA, Cantor SB, Thach CT, Spann SJ. Aspirin for primary prevention of cardiovascular events. J Gen Intern Med. 1998;13(12): 824-835.
52. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006; 144(5): 326-336.
53. Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care. 2010;33 (8): 1859-1864.
54. Currie CJ, Morgan CL, Poole CD, Sharplin P, LammertM, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006; 22(8): 1523-1534.
55. Hayward RA, ManningWG, Kaplan SH,Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA. 1997;278(20): 1663-1669.
56. Leal J, Gray AM, Clarke PM. Development of life-expectancy tables for people with type 2 diabetes. Eur Heart J. 2009;30(7): 834-839.
57. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5): 383-393.
58. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach-position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6): 1577-1596.
59. Aron D, Conlin PR, Hobbs C, Vigersky RA, Pogach L. Individualizing glycemic targets in type 2 diabetes mellitus. Ann Intern Med. 2011;155(5): 340-341.
60. StrainWD, Lukashevich V, KothnyW, Hoellinger M-J, Paldánius PM. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet. 2013;382(9890): 409-416.
61. Price HC, Thorne KI, Dukát A, Kellett J. European physicians overestimate life expectancy and the likely impact of interventions in individuals with type 2 diabetes. Diabet Med. 2009;26(4): 453-455.
62. Loxterkamp D. Humanism in the time of metrics-an essay by David Loxterkamp. BMJ. 2013; 347: f5539.
63. Hayward RA. All-or-nothing treatment targets make bad performance measures. Am J Manag Care. 2007;13(3): 126-128.
64. Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med. 2010;152(2): 69-77.
65. Eddy DM. Designing a practice policy: standards, guidelines, and options. JAMA. 1990;263(22): 3077, 3081, 3084.
66. Management of Diabetes Mellitus Update Working Group. VA/DoD Clinical Practice Guideline for the Management of Diabetes Mellitus. Version 4.0.Washington, DC: Veterans Health Administration and Department of Defense; 2010.
67. Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S,Woerle H-J. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9902): 1413-1423.
68. Food and Drug Administration. Guidance for Industry: Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 2008. http://www.fda .gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM071627.pdf. Accessed October 24, 2013.
69. Food and Drug Administration. Summary Minutes of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting. 2012. http://www .fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM340145.pdf. Accessed October 24, 2013.
70. Scirica BM, Bhatt DL, Braunwald E, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14): 1317-1326.
71. White WB, Cannon CP, Heller SR, et al; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14): 1327-1335.
72. Légaré F, Turcotte S, Stacey D, Ratté S, Kryworuchko J, Graham ID. Patients' perceptions of sharing in decisions: a systematic review of interventions to enhance shared decision making in routine clinical practice. Patient. 2012;5(1): 1-19.